In the preclinical setting, inhibitors of BCLXL or MCL1 showed strong synergistic killing when combined with venetoclax in resistant AML cell line models with elevated levels of these alternative proapoptotic proteins [107]. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.